Xtandi - Beechwood Capital

Xtandi enzalutamide APPROVED

Drug Profile

ModalitySmall molecule

RoutePO

Therapy AreaOncology

Launch2012-08-31

US LOE2027-08-31

Peak Sales Est$7000M

Formulations[{"id":"xtandi-capsule","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":

Companies

PFE (CO_DEVELOPER)50%

ALPMY (ORIGINATOR)50%

Mechanism: Androgen receptor inhibitor

Expert: Second-generation androgen receptor antagonist with higher binding affinity than first-gen agents.

Everyday: Blocks testosterone signaling that fuels prostate cancer growth.

Targets: ["AR"]

Revenue History

Programs (3)

Indication	Stage	Key Study	Regional Status
mCRPC	APPROVED	AFFIRM/PREVAIL	[{"stage":"APPROVED","region":"US","approval_date":"2012-08-31"}]
nmCRPC	APPROVED	PROSPER	[{"stage":"APPROVED","region":"US","approval_date":"2018-07-13"}]
mHSPC	APPROVED	ARCHES/ENZAMET	[{"stage":"APPROVED","region":"US","approval_date":"2019-12-16"}]

Upcoming Catalysts (1)

XTANDI - US Patent Expiration Preparation US: 2027

Notes

Prostate cancer blockbuster. ~$6B peak sales. Major LOE 2027 (US). Partnered with Pfizer.

Data from Supabase · Updated 2026-03-24